# 1stdibs.com, Inc.: financial statements, quarterly

DIBS · Nasdaq · CIK 1600641 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dibs.md) · [Financials](/companies/dibs/financials.md) · [Filings](/companies/dibs/filings.md) · [Insiders](/companies/dibs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dibs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [20.7](/filings/0001600641-24-000194.md) | [20.9 d](/filings/0001600641-26-000007.md) | [22.1](/filings/0001600641-25-000057.md) | [22.2](/filings/0001600641-25-000113.md) | [21.2](/filings/0001600641-25-000130.md) | [22.8 d](/filings/0001600641-26-000007.md) | [22.5](/filings/0001600641-26-000019.md) | [22.1](/filings/0001600641-26-000035.md) | [22.0](/filings/0001600641-25-000130.md) | [23.0 d](/filings/0001600641-26-000007.md) | [22.4](/filings/0001600641-26-000019.md) | [23.3](/filings/0001600641-26-000035.md) |
| Cost of revenue | $m | [5.5](/filings/0001600641-24-000194.md) | [6.0 d](/filings/0001600641-26-000007.md) | [6.1](/filings/0001600641-25-000057.md) | [6.3](/filings/0001600641-25-000113.md) | [6.2](/filings/0001600641-25-000130.md) | [6.3 d](/filings/0001600641-26-000007.md) | [6.2](/filings/0001600641-26-000019.md) | [6.2](/filings/0001600641-26-000035.md) | [5.6](/filings/0001600641-25-000130.md) | [6.1 d](/filings/0001600641-26-000007.md) | [5.7](/filings/0001600641-26-000019.md) | [6.1](/filings/0001600641-26-000035.md) |
| Gross profit | $m | [15.2](/filings/0001600641-24-000194.md) | [15.0 d](/filings/0001600641-26-000007.md) | [16.0](/filings/0001600641-25-000057.md) | [15.9](/filings/0001600641-25-000113.md) | [15.0](/filings/0001600641-25-000130.md) | [16.5 d](/filings/0001600641-26-000007.md) | [16.3](/filings/0001600641-26-000019.md) | [15.9](/filings/0001600641-26-000035.md) | [16.3](/filings/0001600641-25-000130.md) | [16.9 d](/filings/0001600641-26-000007.md) | [16.7](/filings/0001600641-26-000019.md) | [17.2](/filings/0001600641-26-000035.md) |
| Research and development | $m | [4.5](/filings/0001600641-24-000194.md) | [4.4 d](/filings/0001600641-26-000007.md) | [4.7](/filings/0001600641-25-000057.md) | [5.5](/filings/0001600641-25-000113.md) | [5.5](/filings/0001600641-25-000130.md) | [5.5 d](/filings/0001600641-26-000007.md) | [5.6](/filings/0001600641-26-000019.md) | [5.9](/filings/0001600641-26-000035.md) | [5.9](/filings/0001600641-25-000130.md) | [6.0 d](/filings/0001600641-26-000007.md) | [6.2](/filings/0001600641-26-000019.md) | [6.3](/filings/0001600641-26-000035.md) |
| Operating income | $m | [(5.2)](/filings/0001600641-24-000194.md) | [(5.2) d](/filings/0001600641-26-000007.md) | [(5.4)](/filings/0001600641-25-000057.md) | [(6.5)](/filings/0001600641-25-000113.md) | [(7.4)](/filings/0001600641-25-000130.md) | [(7.0) d](/filings/0001600641-26-000007.md) | [(6.3)](/filings/0001600641-26-000019.md) | [(5.7)](/filings/0001600641-26-000035.md) | [(4.7)](/filings/0001600641-25-000130.md) | [(2.3) d](/filings/0001600641-26-000007.md) | [(3.3)](/filings/0001600641-26-000019.md) | [(2.1)](/filings/0001600641-26-000035.md) |
| Interest expense | $m | [0.0](/filings/0001600641-23-000221.md) | [0.0 d](/filings/0001600641-24-000022.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001600641-24-000194.md) | [0.0 d](/filings/0001600641-26-000007.md) | [0.0](/filings/0001600641-25-000057.md) | [0.0](/filings/0001600641-25-000113.md) | [0.0](/filings/0001600641-25-000130.md) | [0.0 d](/filings/0001600641-26-000007.md) | [0.0](/filings/0001600641-26-000019.md) | [0.0](/filings/0001600641-26-000035.md) | [0.1](/filings/0001600641-25-000130.md) | [0.0 d](/filings/0001600641-26-000007.md) | [0.0](/filings/0001600641-26-000019.md) | [0.0](/filings/0001600641-26-000035.md) |
| Net income | $m | [(3.3)](/filings/0001600641-24-000194.md) | [(2.9) d](/filings/0001600641-26-000007.md) | [(3.3)](/filings/0001600641-25-000057.md) | [(4.4)](/filings/0001600641-25-000113.md) | [(5.7)](/filings/0001600641-25-000130.md) | [(5.2) d](/filings/0001600641-26-000007.md) | [(4.8)](/filings/0001600641-26-000019.md) | [(4.3)](/filings/0001600641-26-000035.md) | [(3.5)](/filings/0001600641-25-000130.md) | [(1.0) d](/filings/0001600641-26-000007.md) | [(2.2)](/filings/0001600641-26-000019.md) | [(1.0)](/filings/0001600641-26-000035.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001600641-24-000194.md) | not reported | [(0.08)](/filings/0001600641-25-000057.md) | [(0.12)](/filings/0001600641-25-000113.md) | [(0.15)](/filings/0001600641-25-000130.md) | not reported | [(0.14)](/filings/0001600641-26-000019.md) | [(0.12)](/filings/0001600641-26-000035.md) | [(0.10)](/filings/0001600641-25-000130.md) | not reported | [(0.06)](/filings/0001600641-26-000019.md) | [(0.03)](/filings/0001600641-26-000035.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001600641-24-000194.md) | not reported | [(0.08)](/filings/0001600641-25-000057.md) | [(0.12)](/filings/0001600641-25-000113.md) | [(0.15)](/filings/0001600641-25-000130.md) | not reported | [(0.14)](/filings/0001600641-26-000019.md) | [(0.12)](/filings/0001600641-26-000035.md) | [(0.10)](/filings/0001600641-25-000130.md) | not reported | [(0.06)](/filings/0001600641-26-000019.md) | [(0.03)](/filings/0001600641-26-000035.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [32.4](/filings/0001600641-24-000194.md) | [37.4](/filings/0001600641-26-000007.md) | [33.7](/filings/0001600641-25-000057.md) | [23.8](/filings/0001600641-25-000113.md) | [22.0](/filings/0001600641-25-000130.md) | [26.0](/filings/0001600641-26-000007.md) | [20.3](/filings/0001600641-26-000019.md) | [22.4](/filings/0001600641-26-000035.md) | [19.9](/filings/0001600641-25-000130.md) | [22.9](/filings/0001600641-26-000035.md) | [20.3](/filings/0001600641-26-000019.md) | [18.9](/filings/0001600641-26-000035.md) |
| Current assets | $m | [151](/filings/0001600641-23-000221.md) | [148](/filings/0001600641-25-000011.md) | [143](/filings/0001600641-24-000067.md) | [121](/filings/0001600641-24-000154.md) | [119](/filings/0001600641-24-000194.md) | [112](/filings/0001600641-26-000007.md) | [110](/filings/0001600641-25-000057.md) | [106](/filings/0001600641-25-000113.md) | [104](/filings/0001600641-25-000130.md) | [102](/filings/0001600641-26-000035.md) | [93.4](/filings/0001600641-26-000019.md) | [83.2](/filings/0001600641-26-000035.md) |
| Total assets | $m | [183](/filings/0001600641-23-000221.md) | [181](/filings/0001600641-25-000011.md) | [179](/filings/0001600641-24-000067.md) | [158](/filings/0001600641-24-000154.md) | [154](/filings/0001600641-24-000194.md) | [146](/filings/0001600641-26-000007.md) | [143](/filings/0001600641-25-000057.md) | [139](/filings/0001600641-25-000113.md) | [135](/filings/0001600641-25-000130.md) | [132](/filings/0001600641-26-000035.md) | [122](/filings/0001600641-26-000019.md) | [110](/filings/0001600641-26-000035.md) |
| Current liabilities | $m | [27.0](/filings/0001600641-23-000221.md) | [27.7](/filings/0001600641-25-000011.md) | [27.3](/filings/0001600641-24-000067.md) | [27.1](/filings/0001600641-24-000154.md) | [28.1](/filings/0001600641-24-000194.md) | [28.5](/filings/0001600641-26-000007.md) | [29.4](/filings/0001600641-25-000057.md) | [27.3](/filings/0001600641-25-000113.md) | [25.9](/filings/0001600641-25-000130.md) | [24.4](/filings/0001600641-26-000035.md) | [24.9](/filings/0001600641-26-000019.md) | [24.8](/filings/0001600641-26-000035.md) |
| Total liabilities | $m | [46.5](/filings/0001600641-23-000221.md) | [46.5](/filings/0001600641-25-000011.md) | [48.5](/filings/0001600641-24-000067.md) | [47.2](/filings/0001600641-24-000154.md) | [47.2](/filings/0001600641-24-000194.md) | [46.5](/filings/0001600641-26-000007.md) | [46.3](/filings/0001600641-25-000057.md) | [43.7](/filings/0001600641-25-000113.md) | [41.2](/filings/0001600641-25-000130.md) | [38.5](/filings/0001600641-26-000035.md) | [37.9](/filings/0001600641-26-000019.md) | [36.6](/filings/0001600641-26-000035.md) |
| Shareholders' equity | $m | [136](/filings/0001600641-24-000194.md) | [134](/filings/0001600641-26-000007.md) | [131](/filings/0001600641-25-000113.md) | [110](/filings/0001600641-25-000130.md) | [107](/filings/0001600641-25-000130.md) | [99.3](/filings/0001600641-26-000035.md) | [96.2](/filings/0001600641-26-000035.md) | [94.9](/filings/0001600641-26-000035.md) | [94.0](/filings/0001600641-25-000130.md) | [93.6](/filings/0001600641-26-000035.md) | [84.0](/filings/0001600641-26-000035.md) | [73.7](/filings/0001600641-26-000035.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2.2) d](/filings/0001600641-24-000194.md) | [(2.1) d](/filings/0001600641-26-000007.md) | [(3.1)](/filings/0001600641-25-000057.md) | [(2.6) d](/filings/0001600641-25-000113.md) | [(0.0) d](/filings/0001600641-25-000130.md) | [2.8 d](/filings/0001600641-26-000007.md) | [(0.1)](/filings/0001600641-26-000019.md) | [(5.1) d](/filings/0001600641-26-000035.md) | [(1.5) d](/filings/0001600641-25-000130.md) | [4.3 d](/filings/0001600641-26-000007.md) | [1.1](/filings/0001600641-26-000019.md) | [(4.8) d](/filings/0001600641-26-000035.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001600641-24-000194.md) | [1.7 d](/filings/0001600641-26-000007.md) | [0.2](/filings/0001600641-25-000057.md) | [0.4 d](/filings/0001600641-25-000113.md) | [0.0 d](/filings/0001600641-25-000130.md) | [1.3 d](/filings/0001600641-26-000007.md) | [0.3](/filings/0001600641-26-000019.md) | [0.1 d](/filings/0001600641-26-000035.md) | [(0.3) d](/filings/0001600641-25-000130.md) | [0.7 d](/filings/0001600641-26-000007.md) | [0.2](/filings/0001600641-26-000019.md) | [0.3 d](/filings/0001600641-26-000035.md) |
| Share repurchases | $m | [1.3 d](/filings/0001600641-24-000194.md) | [2.1 d](/filings/0001600641-26-000007.md) | [2.7](/filings/0001600641-25-000057.md) | [19.2 d](/filings/0001600641-25-000113.md) | [0.9 d](/filings/0001600641-25-000130.md) | [5.0 d](/filings/0001600641-26-000007.md) | [1.8](/filings/0001600641-26-000019.md) | [0.0 d](/filings/0001600641-26-000035.md) | [0.0 d](/filings/0001600641-25-000130.md) | [1.6 d](/filings/0001600641-26-000007.md) | [9.1](/filings/0001600641-26-000019.md) | [11.6 d](/filings/0001600641-26-000035.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [38.7](/filings/0001600641-23-000221.md) | [39.3](/filings/0001600641-24-000067.md) | [39.6](/filings/0001600641-24-000154.md) | [40.0](/filings/0001600641-24-000194.md) | [39.7](/filings/0001600641-25-000057.md) | [38.5](/filings/0001600641-25-000113.md) | [36.7](/filings/0001600641-25-000130.md) | [35.6](/filings/0001600641-26-000019.md) | [35.8](/filings/0001600641-26-000035.md) | [36.3](/filings/0001600641-25-000130.md) | [36.4](/filings/0001600641-26-000019.md) | [34.5](/filings/0001600641-26-000035.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,615,293 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001600641-26-000035.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.